High Yielding Pfizer Looks Bullish (Technical Analysis)

Summary:

  • Pfizer yields 5.57% with a B- dividend safety rating, known for Eliquis and Xeljanz.
  • Technical analysis tools show bullish trends: trading above 30-week EMA, increasing momentum, and improving relative strength.
  • Smart money buying, volume spikes, and breakout from consolidation suggest bullish outlook for Pfizer stock.
Pfizer HQ in New York City

georgeclerk

In this article, I will outline why I think the high yielding pharmaceutical giant Pfizer (NYSE:PFE) looks bullish. Pfizer, known for Eliquis and Xeljanz, yields 5.57% and has a dividend safety rating of B- according to Seeking Alpha. I


Analyst’s Disclosure: I/we have a beneficial long position in the shares of PFE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.


Leave a Reply

Your email address will not be published. Required fields are marked *